| abstract |
The present invention generally relates to the preparation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity to various IFN-α subtypes. In addition, the present invention is directed to anti-IFN-α antibodies for diagnosing and treating disorders associated with increased expression of IFN-α, in particular autoimmune disorders such as insulin dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). It is related to use.n n n n Anti-IFN-α antibodies, IFN-α, antibody fragments, libraries, phage display. |